CMRX - キメリックス （Chimerix Inc.） キメリックスCMRXのチャート
CMRXの企業情報
| symbol | CMRx |
|---|---|
| 会社名 | Chimerix Inc. （キメリックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 チメリックス（Chimerix Inc.）はバイオ医薬品会社である。同社は未充足の医療ニーズに対処する薬品の発見、開発、商業化を行う。同社のリード化合物brincidofovirは天然痘、アデノウイルス（AdV）、およびヒトヘルペスウイルスを含むデオキシリボ核酸（DNA）ウイルスの治療と予防のための経口および静脈内（IV）製剤として開発中である。同社はノロウイルスの予防、治療ためのCMX521の開発を進める。さらに、同社は治療法の乏しいあるいはないウイルス標的に集中するアクティブな発見プログラムがある。Brincidofovirは人間に感染できる5つのファミリーの二本鎖デオキシリボ核酸（dsDNA）ウイルスすべてに対してスペクトル抗ウイルス活性を示した研究用経口ヌクレオチド類似体である。brincidofovirの経口、IV製剤は活性な抗ウイルスをウイルス複製部位に直接送達する開発階段中である。 キメリックスは、米国のバイオ医薬品会社。経口抗ウイルス薬を発見、開発、商品化する。同社は独自の脂質技術を利用し、2種類のヌクレオチド化合物を開発。「Brincidofovir (CMX001)」は第3相臨床段階にある。「CMX157」は第1相臨床試験を終えた後、メルク・シャ―プ・アンド・ド―ム社へライセンス供与した。 Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious diseases. The company's three most advanced clinical-stage development programs are BCV, ONC201 and DSTAT. BCV is an antiviral drug candidate developed as a potential medical countermeasure for smallpox and is currently under review for regulatory approval in the United States. ONC201 is currently in a registrational clinical program for recurrent H3 K27M-mutant glioma and a confirmatory response rate assessment is expected later this year. DSTAT is in development as a potential first-line therapy in acute myeloid leukemia and as a potential treatment for acute lung injury in hospitalized COVID-19 patients. |
| 本社所在地 | 2505 Meridian Parkway Suite 100 Durham NC 27713 USA |
| 代表者氏名 | Martha J. Demski マーサ・J・デムスキー |
| 代表者役職名 | Chairman of the Board 取締役会会長 |
| 電話番号 | +1 919-806-1074 |
| 設立年月日 | 36617 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2013年 |
| 従業員数 | 82人 |
| url | www.chimerix.com |
| nasdaq_url | https://www.nasdaq.com/symbol/cmrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -75.05300 |
| 終値（lastsale） | 3.84 |
| 時価総額（marketcap） | 184420899.84 |
| 時価総額 | 時価総額（百万ドル） 172.89460 |
| 売上高 | 売上高（百万ドル） 4.72400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） -1.86840 |
| 当期純利益 | 当期純利益（百万ドル） -74.98900 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Chimerix Inc revenues increased 13% to $2M. Net loss increased 12% to $38.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 21% to $25.2M (expense) General and administrative increase of 7% to $8.8M (expense). |
CMRXのテクニカル分析
CMRXのニュース
Canada signs $32.9M contract for smallpox drug with manufacturer Chimerix - National | Globalnews.ca 2022/06/24 18:00:54 Global News Canada
Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.
Canada signs $32.9M contract for smallpox drug with manufacturer Chimerix 2022/06/24 18:00:54 Global News Canada
Chimerix Inc. has been awarded a contract by Canada worth up to $32.9 million for its smallpox drug likely to be used to treat monkeypox as it spreads across the world.
Chimerix gets up to $25.3-million contract from Canada for drug likely to be used to treat monkeypox 2022/06/24 15:12:45 The Globe and Mail
The contract, awarded by the Public Health Agency of Canada, comes a day after Chimerix announced an order worth $9.3-million for the smallpox drug, Tembexa
Chimerix ticks higher on new order for smallpox therapy 2022/06/24 15:09:18 Seeking Alpha
The shares of Chimerix (CMRX) rose on Friday after the company announced that Public Health Agency of Canada awarded it a contract to deliver up to $25.3M of Tembexa (brincidofovir),…
Chimerix gets up to $25.3 million contract from Canada for smallpox drug 2022/06/24 14:50:46 Reuters
Chimerix Inc said on Friday it had been awarded a contract worth up to $25.3 million by Canada for its smallpox drug, likely to used to treat monkeypox as the viral infection spreads across the world.
7 Monkeypox Stocks That May Take Off in Q2 2022/06/09 10:28:31 InvestorPlace
Once a problem confined to just one continent, Monkeypox is spreading and threatens to become a global issue. Since the United Kingdom first reported a confirmed Monkeypox case on May 7, many more cases have been reported in countries where the virus hasn’t been originally known to be present. Nearly 800 cases have been detected so far, and investors are rightfully researching Monkeypox stocks to buy to position themselves for a potential upside during the second quarter of 2022. According to the World Health Organization (WHO), Monkeypox is a rare viral disease similar to smallpox but considered clinically less severe. It has been endemic in West Africa and Central Africa. Since it’s a viral disease, vaccination is the best front-line defense. It is widely believed that Smallpox vaccines are adequate for Monkeypox immunity. Unlike the Covid-19 scenario, when the world was vastly unprepared for a coronavirus outbreak, vaccines are already available for every American citizen should there be a Smallpox outbreak.
Chimerix Inc. (CMRX) Shares Are Down -70.92% YTD 2022/06/08 11:30:00 Marketing Sentinel
Chimerix Inc. (NASDAQ:CMRX) has a beta value of 1.34 and has seen 2.85 million shares traded in the last trading session. The company, currently valued at $158.30M, closed the last trade at $1.87 per share which meant it gained $0.09 on the day or 5.06% during that session. The CMRX stock price is -375.4% off … Chimerix Inc. (CMRX) Shares Are Down -70.92% YTD Read More »
Bluebird Bio, Clovis Oncology Chimerix drop as Truist flags liquidity concerns 2022/06/02 13:59:50 Seeking Alpha
Bluebird Bio (BLUE), Clovis Oncology (CLVS) and Chimerix (CMRX) are trading lower in the morning hours Thursday after Truist said that the three biotechs are at the risk of running out…
Chimerix to Present at Jefferies Global Healthcare Conference 2022/06/01 20:30:00 GlobeNewswire
DURHAM, N.C., June 01, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Sherman, Chief Executive Officer, will present a corporate overview at the upcoming Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 3:30 p.m. in New York City.
Futures Jump After Biden Says Trump''s China Tariffs Under Consideration 2022/05/23 11:49:24 Zero Hedge
Futures Jump After Biden Says Trump''s China Tariffs Under Consideration US stock futures advanced for a second day after staging a furious rally late on Friday having slumped into a bear market just hours earlier, after President Joe Biden said China tariffs imposed by the Trump administration were under consideration, although concerns about hawkish central banks and record Covid cases in Beijing continued to weigh on the sentiment. Contracts on the S&P 500 were up 1% by 7:15 a.m. in New York, trimming earlier gains of as much as 1.4% following remarks from Christine Lagarde that the European Central Bank is likely to start raising interest rates in July and exit sub-zero territory by the end of September which sent the euro sharply higher and hit the USD. Meanwhile, Beijing and Tianjin continue to ramp up Covid restrictions as cases climbed. Nasdaq futures also jumped, rising 1.1%. Europe rose 0.6% while Asian stocks closed mostly in the green, with Nikkei +1% and Hang Seng -1.2%. The dollar and Treasuries retreated, while bitcoin jumped to $30,500 as the crypto rout appears over.
Chimerix to Present at H.C. Wainwright 23rd Annual Global Investment Conference 2021/09/07 11:00:00 Intrado Digital Media
DURHAM, N.C., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company focused on accelerating the development of medicines to treat cancer and other serious diseases, today announced that Mike Sherman, Chief Executive Officer of Chimerix and Mike Andriole, Chief Financial and Business Officer of Chimerix, will participate in a pre-recorded fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference that will be made available on Monday, September 13, 2021 at 7:00 a.m. ET.
Rhabdoid Tumor Treatment Market SWOT Analysis, Key Indicators, Forecast 2028 : Takeda Pharmaceutical Company Limited, Chimerix, Epizyme, Inc., Vyriad, DNAtrix, Lantern Pharma, Inc., and Pfizer Inc 2021/08/31 09:57:38 OpenPR
Global rhabdoid tumor treatment market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 6.10% in the above mentioned forecast